SCNXHealthcare · Pharmaceutical RetailersSCNX Stock Forecast: Scienture Holdings, Inc. Price Predictions for 2026-2027
The 1 Wall Street analysts covering Scienture Holdings, Inc. hold a median 12-month price target of $1.5 — +287.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 11 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
SCNX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Scienture Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
The rank is the raw material. Whether the rules would actually own Scienture Holdings, Inc. — and when they’d sell — is the membership.
SCNX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SCNX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +287.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Feb 2026 | Maxim Group | Initiates | Buy | $1.50 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SCNX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Scienture Holdings, Inc. (SCNX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 0.6×
- Price / sales
- 32.9×
- Price / book
- 0.2×
- EV / EBITDA
- −0.8×
Cheaper than 71% of US stocks
Cheaper than 7% of US stocks
Cheaper than 88% of US stocks
Cheaper than 67% of US stocks
- Revenue growth (YoY)
- 449.1%
- Earnings growth (YoY)
- 449.1%
- Gross margin
- 95.6%
- Operating margin
- −6230.8%
- Net margin
- 76.8%
Higher than 98% of US stocks
Higher than 95% of US stocks
Higher than 99% of US stocks
Higher than 3% of US stocks
Higher than 98% of US stocks
- Return on equity
- −56.6%
- Return on assets
- −10.8%
- Dividend yield
- 1550.4%
Higher than 19% of US stocks
Higher than 26% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
SCNX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| SCNXScienture Holdings, Inc. | $15.8M | 11 |
| PETSPetMed Express, Inc. | $41.7M | 55 |
| HITIHigh Tide, Inc. | $185.0M | 58 |
| ZJYLJin Medical International Ltd.* | $15.5M | 19 |
| KTTAPasithea Therapeutics Corp.* | $15.4M | 21 |
| CTXRCitius Pharmaceuticals, Inc.* | $15.6M | 27 |
| OSRHOSR Health, Inc.* | $15.7M | 23 |
* Nearest Healthcare names by size — few pharmaceutical retailers companies of this scale trade in the US universe.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCNX appears on the weeks it earns a place.
Frequently asked questions about SCNX stock
What is the SCNX stock price forecast for 2026-2027?
The 1 Wall Street analysts covering Scienture Holdings, Inc. have a median 12-month price target of $1.5, with estimates ranging from $1.5 to $1.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SCNX stock a buy right now?
Of the 1 analysts covering Scienture Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scienture Holdings, Inc. 11 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SCNX?
As at 1 Aug 2026, Scienture Holdings, Inc. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
Will SCNX stock go up?
No one can know that. What the data says: the median 12-month target from 1 analysts implies +287.6% from the last close, and Ticker Nerd's factor model ranks Scienture Holdings, Inc. 11 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SCNX stock forecast for 2030?
No analyst covering Scienture Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $1.5 over the next 12 months.
How has SCNX stock performed over the past year?
Scienture Holdings, Inc. returned -79.7% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Scienture Holdings, Inc. do?
Scienture Holdings operates as a specialty pharmaceutical company through its wholly owned subsidiary Scienture, LLC, focusing on developing and commercializing branded pharmaceutical products for central nervous system and cardiovascular diseases in the United States. The company's current commercial portfolio includes Arbli, an FDA-approved oral suspension formulation of losartan potassium for treating hypertension and related cardiovascular conditions, and REZENOPY, a naloxone nasal spray for emergency opioid overdose treatment.
About Scienture Holdings, Inc.
Scienture Holdings operates as a specialty pharmaceutical company through its wholly owned subsidiary Scienture, LLC, focusing on developing and commercializing branded pharmaceutical products for central nervous system and cardiovascular diseases in the United States. The company's current commercial portfolio includes Arbli, an FDA-approved oral suspension formulation of losartan potassium for treating hypertension and related cardiovascular conditions, and REZENOPY, a naloxone nasal spray for emergency opioid overdose treatment. Scienture maintains a pipeline of investigational candidates spanning therapeutic areas including pain management and thrombosis. The company operates through two segments: Scienture, which focuses on branded pharmaceutical development and commercialization, and Integra, which engages in wholesale distribution of licensed pharmaceutical brands, generics, and non-drug products. Scienture has established partnerships with major wholesalers, health plans, and group purchasing organizations to distribute its products across retail, institutional, and long-term care settings. Founded in 2010 and based in the United States, the company leverages intellectual property protection, including patents listed in the FDA Orange Book, to support its specialty pharmaceutical strategy.
CEO Dr. Shankar Hariharan Ph.D. · 4 employees · United States · https://scienture.com